Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Rallybio Corporation (RLYB : NSDQ)

• Company Description    Rallybio Corporation is a clinical-stage biotechnology company committed to identifying and accelerating the development of therapies for patients with severe and rare diseases. Rallybio Corporation is headquartered in New Haven, Connecticut. Number of Employees: 14

• Price / Volume Information    Yesterday's Closing Price: $15.88 Daily Weekly Monthly 20 Day Moving Average: 646,322 shares Shares Outstanding: 5.30 (millions) Market Capitalization: $84.13 (millions) Beta: -1.10 52 Week High: $16.00 52 Week Low: $2.16 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 86.82% 77.70% 12 Week 133.53% 115.89% Year To Date 189.32% 157.62%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 234 CHURCH STREET - NEW HAVEN,CT 06510 USA ph: 203-859-3820 fax: - investors@rallybio.com http://www.rallybio.com

• General Corporate Information    Officers Stephen Uden - Chief Executive Officer; President and Director Martin W. Mackay - Chairman Jonathan I. Lieber - Chief Financial Officer and Treasurer Helen M. Boudreau - Director Wendy K Chung - Director Peer Information Rallybio Corporation (CORR.) Rallybio Corporation (RSPI) Rallybio Corporation (CGXP) Rallybio Corporation (BGEN) Rallybio Corporation (GTBP) Rallybio Corporation (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 75120L209 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/06/26 Share - Related Items Shares Outstanding: 5.30 Most Recent Split Date: 2.00 (0.13:1) Beta: -1.10 Market Capitalization: $84.13 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.67 Price/Cash Flow: - Price / Sales: 98.06 EPS Growth vs. Year Ago Period: 13.10% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: -4.50% ROE 03/31/26 - -55.79 12/31/25 - -56.93 09/30/25 - -65.23 ROA 03/31/26 - -51.48 12/31/25 - -52.67 09/30/25 - -59.90 Current Ratio 03/31/26 - 12.92 12/31/25 - 14.51 09/30/25 - 14.74 Quick Ratio 03/31/26 - 12.92 12/31/25 - 14.50 09/30/25 - 14.74 Operating Margin 03/31/26 - -3,531.00 12/31/25 - -3,666.32 09/30/25 - -5,437.54 Net Margin 03/31/26 - -911.07 12/31/25 - -1,046.39 09/30/25 - -2,102.37 Pre-Tax Margin 03/31/26 - -877.62 12/31/25 - -944.52 09/30/25 - -1,908.90 Book Value 03/31/26 - 9.49 12/31/25 - 10.98 09/30/25 - 12.07 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©